Health ❯ Healthcare ❯ Pharmaceuticals

Drug Approvals

FDA Approvals Eli Lilly Lecanemab Pfizer Inc. Deflazacort Tablets Niacin Extended-Release Tablets NHS Spending Inluriyo Market Competition Wegovy Kisunla Revumenib Eylea HD Libtayo Approval Novo Nordisk Cancer Treatments Clinical Guidelines

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

The decision follows phase 3 results showing a roughly 14-month median progression-free survival advantage over the THP regimen.

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC